| Vol. 14.17 – 13 May, 2022 |
| |
|
|
Single-Cell eQTL Models Reveal Dynamic T Cell State Dependence of Disease Loci | Using more than 500,000 unstimulated memory T cells from 259 Peruvian individuals, scientists showed that around one-third of 6,511 cis-expression quantitative trait loci (eQTLs) had effects that were mediated by continuous multimodally defined cell states, such as cytotoxicity and regulatory capacity. [Nature] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
Reversible CD8 T Cell–Neuron Cross-Talk Causes Aging-Dependent Neuronal Regenerative Decline | Researchers identified an aging-dependent mechanism that relied on the CXCL13-dependent recruitment and activation of CXCR5+CD8+ T cells in proximity to sensory neurons that restricted axonal regeneration after nerve injury after communication with MHC I–presenting dorsal root ganglia neurons. [Science] |
|
|
|
Rapid, Site-Specific Labeling of “Off-the-Shelf” and Native Serum Autoantibodies with T Cell–Redirecting Domains |
|
|
Investigators developed a simple method to site-specifically and covalently attach a T cell–redirecting domain to any off-the-shelf, human immunoglobulin G (IgG) or native IgG isolated from serum. [Science Advances] |
|
|
|
The Immune Checkpoint B7x Expands Tumor-Infiltrating Tregs and Promotes Resistance to Anti-CTLA-4 Therapy | The authors showed that transduction and stable expression of B7x in multiple syngeneic tumor models led to the expansion of immunosuppressive Tregs. [Nature Communications] |
| Hypoxia Induces Adrenomedullin from Lung Epithelia, Stimulating ILC2 Inflammation and Immunity |
|
|
Researchers reported that conditional deletion of the E3 ubiquitin ligase VHL in lung epithelial cells resulted in exacerbated type 2 responses accompanied by selective increase of group 2 innate lymphoid cells (ILC2s) at steady state and following inflammation or helminth infection. [Journal of Experimental Medicine] |
| LAMP2 Regulates Autophagy in the Thymic Epithelium and Thymic Stroma-Dependent CD4 T Cell Development | Scientists showed that lysosomal-associated membrane protein 2 (LAMP2) was highly expressed in cortical thymic epithelial cells and that genetic inactivation of Lamp2 in thymic stromal cells impaired the development of CD4 T cells that completed positive selection. [Autophagy] |
|
|
|
Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101 | In syngeneic murine models, ATRC-101 demonstrated robust antitumor activity and evidence of immune memory following rechallenge of cured mice with fresh tumor cells. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
The Kinase p38α Functions in Dendritic Cells to Regulate Th2-Cell Differentiation and Allergic Inflammation | The authors showed that p38α activity in dendritic cells was decreased upon house dust mite stimulation and dynamically regulated by both extrinsic signals and T helper 2 (Th2)-instructive cytokines. [Cellular & Molecular Immunology] |
|
|
|
Aryl Hydrocarbon Receptor Signals in Epithelial Cells Govern the Recruitment and Location of Helios+ Tregs in the Gut | Scientists administered indigo naturalis (IN), a nontoxic phytochemical aryl hydrocarbon receptor agonist used for treating patients with ulcerative colitis in Asia, and showed that IN increased Helios+ Tregs and MHC class II+ epithelial cells in the colon. [Cell Reports] |
|
|
|
HOIL1 Regulates Group 2 Innate Lymphoid Cell Numbers and Type 2 Inflammation in the Small Intestine | To investigate the role of HOIL1 in regulating intestinal inflammation, researchers employed a mouse model of partial HOIL1 deficiency. [Mucosal Immunology] |
|
|
|
Tim-3+ Decidual Mφs Induced Th2 and Treg Bias in Decidual CD4+ T Cells and Promoted Pregnancy Maintenance via CD132 | Investigators found a higher frequency of T cell immunoglobulin mucin-3 (Tim-3)+ decidual macrophages (Mφs) in response to trophoblasts. The reduced abundance of Tim-3 on Mφs was accompanied by disordered anti- and pro-inflammatory cytokine profiles in miscarriage. [Cell Death & Disease] |
|
|
|
Human CD4+/CD8α+ Regulatory T Cells Induced by Faecalibacterium prausnitzii Protect against Intestinal Inflammation | Scientists demonstrated a protective effect of an HLA-DR*0401-restricted DP8α Treg clone combined with F. prausnitzii administration in a colitis model. [JCI Insight] |
|
|
|
Maternal-Fetal Conflict Averted by Progesterone Induced FOXP3+ Regulatory T Cells | The authors showed that the female reproductive hormone, progesterone, coordinated immune tolerance by stimulating the expansion of FOXP3+ regulatory T cells. [iScience] |
|
|
|
|
Macrophage Functional Diversity in NAFLD — More than Inflammation | Scientists reveal hepatic macrophage function beyond their classically described inflammatory role in the progression of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis pathogenesis. [Nature Reviews Endocrinology] |
|
|
|
Thymic and Extrathymic Aire-Expressing Cells in Maternal-Fetal Tolerance | Investigators summarize findings related to essential Aire biology, discuss the known roles of Aire-deficiency related to pregnancy complications and infertility, and review the newly discovered role for extrathymic Aire-expressing cells (eTACs) in the maintenance of maternal-fetal tolerance. [Immunological Reviews] |
|
|
|
Therapeutic Opportunities to Modulate Immune Tolerance through the Metabolism-Chromatin Axis | The authors evaluate novel possibilities for developing therapeutic strategies to modulate immune tolerance through metabolism via epigenetic drugs. [Trends in Endocrinology and Metabolism] |
|
|
|
|
NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes | NexImmune, Inc., Yale, and JDRF have begun a two-year project to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells. [NexImmune, Inc.] |
|
|
|
NGM Bio Announces Initiation of Phase I/Ib Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors | NGM Biopharmaceuticals, Inc. announced it has initiated a Phase I/Ib clinical study of NGM438 for the treatment of patients with advanced solid tumors. [NGM Biopharmaceuticals, Inc.] |
|
|
|
|
| June 15 – 18, 2022 San Francisco, California, United States |
|
|
|
|
|
| University of Oxford – Oxford, England, United Kingdom |
|
|
|
| STEMCELL Technologies, Inc. – Vancouver, British Columbia, Canada |
|
|
|
| Cancer Research Center of Lyon – Lyon, France |
|
|
|
| The Pirbright Institute – Pirbright, England, United Kingdom |
|
|
|
| New York University College of Dentistry – New York, New York, United States |
|
|
|
|